Last reviewed · How we verify
Formoterol Inhalation Solution
Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).
At a glance
| Generic name | Formoterol Inhalation Solution |
|---|---|
| Also known as | PERFOROMIST® 20 μg/ 2 mL vial, 1 vial BID |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and airway dilation. As a long-acting formulation, it provides sustained bronchodilation for 12 hours or longer, making it suitable for maintenance therapy in chronic obstructive airway diseases. The inhalation solution formulation allows direct delivery to the lungs for rapid local effect.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma (maintenance therapy)
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD (PHASE2)
- Formoterol in Diabetes (PHASE2)
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (PHASE3)
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid (PHASE3)
- Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Formoterol Inhalation Solution CI brief — competitive landscape report
- Formoterol Inhalation Solution updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI